X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1516) 1516
Publication (216) 216
Book Chapter (25) 25
Book Review (17) 17
Conference Proceeding (11) 11
Dissertation (2) 2
Magazine Article (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
telaprevir (1500) 1500
index medicus (1020) 1020
humans (985) 985
boceprevir (709) 709
hepatitis c (695) 695
ribavirin (654) 654
hepatitis c virus (617) 617
hepatitis c, chronic - drug therapy (594) 594
antiviral agents - therapeutic use (569) 569
gastroenterology & hepatology (529) 529
male (528) 528
female (495) 495
hepacivirus - genetics (482) 482
middle aged (459) 459
drug therapy, combination (415) 415
genotype (407) 407
interferon (382) 382
adult (352) 352
treatment outcome (349) 349
ribavirin - therapeutic use (339) 339
hepatitis (324) 324
peginterferon (320) 320
protease inhibitors (312) 312
hepacivirus - drug effects (304) 304
virus-infection (294) 294
interferon-alpha - therapeutic use (285) 285
aged (269) 269
hepatitis c, chronic - virology (253) 253
pharmacology & pharmacy (253) 253
therapy (250) 250
plus ribavirin (249) 249
infectious diseases (246) 246
genotype 1 infection (241) 241
oligopeptides - therapeutic use (241) 241
antiviral agents - adverse effects (239) 239
virology (239) 239
antiviral agents - administration & dosage (238) 238
hepatitis c - drug therapy (238) 238
antiviral agents (231) 231
polyethylene glycols - therapeutic use (230) 230
pegylated interferon (223) 223
hcv (222) 222
proline - analogs & derivatives (222) 222
biological response modifiers (217) 217
infection (210) 210
health aspects (209) 209
sustained virological response (205) 205
care and treatment (193) 193
proteases (184) 184
drug therapy (182) 182
recombinant proteins - therapeutic use (177) 177
genetic aspects (166) 166
analysis (164) 164
chronic hepatitis-c (163) 163
sofosbuvir (163) 163
gastroenterology and hepatology (158) 158
ribavirin - administration & dosage (157) 157
chronic hepatitis c (152) 152
viral load (151) 151
virus diseases (151) 151
antiviral agents - pharmacology (150) 150
proline - therapeutic use (144) 144
protease inhibitor (134) 134
cirrhosis (130) 130
interferon-alpha - administration & dosage (127) 127
protease inhibitors - therapeutic use (126) 126
genotype 1 (124) 124
liver cirrhosis (124) 124
young adult (124) 124
rna, viral - blood (123) 123
triple therapy (122) 122
oligopeptides - adverse effects (121) 121
peginterferon alpha-2a (119) 119
simeprevir (119) 119
combination (117) 117
liver (117) 117
hepatitis c - virology (115) 115
genotype & phenotype (113) 113
microbiology (113) 113
polyethylene glycols - administration & dosage (113) 113
hiv (112) 112
viral nonstructural proteins - antagonists & inhibitors (112) 112
virus (112) 112
hepacivirus - isolation & purification (110) 110
hepatology (109) 109
combination therapy (107) 107
drug resistance, viral (105) 105
treatment-naive patients (105) 105
medicine, general & internal (103) 103
oligopeptides - administration & dosage (100) 100
anemia (98) 98
antiviral therapy (98) 98
resistance (97) 97
infections (96) 96
ribavirin - adverse effects (96) 96
hepacivirus - classification (93) 93
chronic hcv infection (92) 92
rna (92) 92
viral nonstructural proteins - genetics (92) 92
abridged index medicus (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1405) 1405
Spanish (51) 51
Hungarian (20) 20
German (19) 19
Japanese (17) 17
French (16) 16
Russian (7) 7
Czech (5) 5
Turkish (3) 3
Korean (2) 2
Croatian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Materials Science & Engineering C, ISSN 0928-4931, 12/2019, Volume 105, p. 110012
Telaprevir (TVR) is typically a poorly soluble drug with an extremely low bioavailability of 1.7%. Polymorph modifications cannot improve the solubility of TVR... 
Polymer, Solubility | Solid dispersion | Cytotoxicity | Telaprevir | Dissolution
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 07/2013, Volume 31, pp. 2 - 6
Telaprevir es el primero de una generación de medicamentos basados en ensamblar andamiajes moleculares con enzimas codificadas por el virus de la hepatitis C,... 
Telaprevir metabolism | Inhibición NS3-4A | Telaprevir pharmacokinetics | CYP3A4 inhibition | Inhibición CYP3A4 | NS3-4A inhibition | Metabolismo de telaprevir | Farmacocinética de telaprevir
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 12/2014, Volume 59, Issue 12, pp. 1777 - 1778
Journal Article
Hepatology, ISSN 0270-9139, 06/2013, Volume 57, Issue 6, pp. 2143 - 2154
Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.... 
NONRESPONSE | TELAPREVIR | THERAPY | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2A | BI 201335 | PHARMACOKINETICS | PROTEASE INHIBITOR BI201335 | 1 INFECTION | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 60, Issue 1, pp. 78 - 86
Background & Aims: Protease inhibitors (PI) with peginterferon/ ribavirin have significantly improved SVR rates in HCV G1 patients. Their use to treat HCV... 
Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 9, pp. 1525 - 1529
To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR)... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
Journal Article
Journal Article
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017
In this study, a nationwide database was used to identify the risk factors for treatment discontinuation due to adverse events during telaprevir,... 
regional differences | ribavirin | telaprevir | nationwide database | hepatitis C | interferon
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
Journal Article